Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00555971
Other study ID # IRB 05-066
Secondary ID Q3637s
Status Completed
Phase Phase 4
First received
Last updated
Start date May 2006
Est. completion date February 2016

Study information

Verified date October 2020
Source The Cleveland Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a 24 week double-blind study in which subjects will be randomized 2:1 to receive Xolair (Omalizumab) or placebo. 14 subjects will receive Xolair and 7 will receive placebo. Xolair injections will occur every 2-4 weeks. Aspirin desensitization will occur several weeks later. One month after desensitization, the final visit will occur in the GCRC. We hypothesize that administration of Xolair, a monoclonal anti-IgE antibody, prior to the aspirin desensitization will reduce severity of aspirin-induced reaction.


Description:

This is a 24 week double-blind study consisting of up to 11 office visits for people 18 years of age with aspirin exacerbated respiratory disease (AERD). 21 subjects will participate and will be randomized 2:1 to receive Xolair (Omalizumab) or placebo. 14 subjects will receive Xolair and 7 will receive placebo. Xolair is a FDA approved medication for the treatment of moderate to severe allergic asthma. Injections will occur every 2-4 weeks, for 16 weeks. The dosage will be based upon IgE and body weight. Aspirin desensitization will occur 1-3 weeks later. One month after desensitization, the final visit will occur in the GCRC. Properly selected patients with aspirin exacerbated respiratory disease (AERD) experience benefit in the course of their disease with aspirin desensitization treatment; however, AERD patients are at risk for potentially serious asthmatic reaction when undergoing aspirin desensitization. For this reason, this procedure is currently performed in a monitored setting. We hypothesize that administration of Xolair, a monoclonal anti-IgE antibody, prior to the aspirin desensitization will reduce severity of aspirin-induced respiratory reaction, and that ultimately, use of Xolair will permit this procedure to be performed safely in outpatient settings. This protocol also entails obtaining blood and urine samples to assess the influence of Xolair, compared with placebo. As aspirin induced reaction occurs via heightened release of leukotrienes combined with greater end organ responsiveness to these mediators, we also will be quantifying the impact of prior administration of Xolair, compared with placebo, on the elevation of urinary LTE4 in association with aspirin challenge and with aspirin provoked reaction.


Read more »

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Omalizumab
Subjects randomized to Omalizumab prior to aspirin desensitization
placebo
Subjects randomized to Placebo prior to aspirin desensitization

Locations

Country Name City State
United States The Cleveland Clinic Cleveland Ohio

Sponsors (2)

Lead Sponsor Collaborator
David Lang Genentech, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants Without Respiratory Reaction During Aspirin Desensitization Lack of Respiratory reaction during aspirin desensitization, including Spirometry (FEV1) testing, to assess the efficacy of Xolair on attenuating aspirin induced bronchospasm in patients with AERD. 24 weeks
Secondary Measurements of Urinary LTE4 in Association With Respiratory Reaction During Aspirin Desensitization Measurements of urinary LTE4 in association with aspirin desensitization, comparing subjects randomized to placebo with subjects randomized to omalizumab, with study drug administered for 16 weeks. Measurements were compared for respiratory reaction in placebo subjects who exhibited either upper or lower airway reaction and after 100 mg aspirin challenge dose in omalizumab subjects who were non-reactors. For this analysis, the two omalizumab subjects who had respiratory reaction were not included. Approximately 24 weeks
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03704415 - Aggravated Airway Inflammation: Research on Genomics and Optimal Operative Treatment (AirGOs Operative) N/A
Completed NCT03188705 - CES1 Carriers in the PAPI Study Phase 4
Completed NCT01778465 - Effect of Dietary Salicylate in Aspirin Exacerbated Respiratory Disease N/A
Completed NCT03849625 - Characteristics of Patients Diagnosed With NSAID Sensitivity in Thailand
Recruiting NCT05511441 - Routine Minimally Invasive Thoracic Surgery Without Aspirin Withdraw N/A
Completed NCT04040465 - Asprin Dosing Estimator in Healthy Adults Early Phase 1